Poolbeg Pharma (OTC:POLBF) Stock, Quote.Headers.trade-ideas

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma PLC

News

Offerings

ARQQ

Arqit Quantum Files For Mixed Shelf Of Up To $150M

Insider Trades

COIN

Coinbase Global Form 4 Filing Shows CFO Alesia J Haas Sold 27,441 Shares Of Stock At An Average Price Of $291.02/Share

Asset Sales

Frederick Ernest Ehrsam III Reported A 2.87% Passive Stake In Coinbase Global As Of Dec 31, 2024 Vs 7.57% On Sept 30, 2024

NARI

Stryker Commences Tender Offer For All Outstanding Shares Of Common Stock Of Inari Medical For $80/Share In Cash

Legal

Spirit Faces Multiple Lawsuits Alleging Omission of Material Information in Merger Proxy; Actions Filed Across New York, Kansas, and Delaware Courts Seeking Injunctive Relief; Spirit Supplements Disclosures to Moot Claims, Denies Allegations

Jackson Financial Inc Files For Mixed Shelf; Size Not Disclosed

Analysts turn their focus to the 2025 movie season, offering box office predictions as the industry grapples with the continued <a href="https://www.benzinga.com/topic/streaming">rise of streaming platforms.</a>
JPMorgan 2025 Outlook: The movie theater industry <a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">could be normalizing</a> after facing the COVID-19 pandemic disruption and labor stoppages, JPMorgan analyst David Karnovsky said in a new investor note.
"The key headwind for theaters remains supply – COVID and strike-related production shutdowns hampered output, and while the impacts are yet to be fully overcome, the lack of ongoing constraints sets up the conditions for a full recovery in volume by 2026 or 2027," Karnovsky said.
The analyst forecasts the North American box office to hit $9.50 billion in 2025, up 10.8% year-over-year. Broken down by quarter, Karnovsky's predictions are as follows:
<ul>
<li>Q1: $1.77 billion, +9.7% year-over-year</li>
<li>Q2: $2.44 billion, +25.1% year-over-year</li>
<li>Q3: $2.57 billion, -3.7% year-over-year</li>
<li>Q4: $2.73 billion, +16.2% year-over-year</li>
</ul>
While the report does not share price targets for movie theater stocks, Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) and IMAX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) are named in the report. AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) would be another stock to watch, given the potential increase in domestic 2025 box office revenue.
"While our forecast builds for significant growth, we believe it is below some of the more bullish estimates for $10b-plus which followed strong performance during the holiday period."
The analyst said he remains constructive on the movie theater industry given the rise of the streaming market, specifically increased film output from Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). The rise of Netflix and streaming platforms has shortened theatrical release windows for movies.
"While these forces have delivered real stress to the ecosystem, with some hindsight, it appears many of the bear theses that existed pre-pandemic were overblown."
The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) is also featured several times in the report, with Karnovsky highlighting upcoming movies like "Zootopia 2," "Snow White," "Lilo &amp; Stitch," "Captain America: Brave New World," "Fantastic Four" and "Avatar: Fire and Ash."
Disney is also highlighted for the early 2026 outlook with movies like "Toy Story 5," a live-action "Moana", "Avengers: Doomsday" and "The Mandalorian &amp; Grogu."
Read Also: <a href="https://www.benzinga.com/24/12/42603589/disney-hits-2-billion-domestic-box-office-wins-top-honors-global-box-office-2025-to-grow-8-to-33b-analyst-says">Disney Hits $2 Billion Domestic Box Office, Earns Top Honors</a>
Goldman Sachs on Movie Theater Stocks: Goldman Sachs analyst Stephen Laszczyk has a domestic box office revenue estimate of $9.4 billion for 2026.
Laszczyk projects a recovery to 82% of 2019 revenue levels, after which earnings would likely remain range-bound.
In the recent report, the analyst highlights IMAX and Cinemark as the two covered stocks in the sector.
The analyst has a Sell rating on Imax with a $16 price target. Despite the sell rating, the analyst sees several scenarios that could provide upside risk to the rating.
"Box office demand could recover more quickly and on a larger scale than expected," Laszczyk said.
The analyst said movie theaters could look to add more Imax screens. A change in China's policy to allow more American blockbusters in the country could also benefit Imax, the analyst added.
"IMAX may benefit from uplifts in ticket prices as studios and exhibitors look to increase revenue."
The analyst also has a Sell rating on Cinemark with a $24 price target.
Similar to Imax, the analyst said there are several scenarios that could provide upside for the movie theater stock.
Along with box office demand recovering faster than expected, the analyst said better food and beverage margins and lower operating expenses could help Cinemark.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/43017986/warner-bros-discovery-analyst-says-dtc-strength-wont-offset-joker-folie-a-deux-flop-nba-rights-concerns">Warner Bros. Discovery Analyst Says DTC Strength Won&#8217;t Offset &#8216;Joker: Folie A Deux&#8217; Flop, NBA Rights Concerns</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Entertainment

Price Target

Reiteration

Analyst Ratings

Trading Ideas

IMAX

NFLX

Box Office Set For $9.5 Billion 2025 Comeback As Netflix Reshapes Industry, Analyst Says

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) reported quarterly earnings of $2.12 per share which beat the analyst consensus estimate of $2.00 by 6 percent. This is a 20.45 percent increase over earnings of $1.76 per share from the same period last year. The company reported quarterly sales of $523.09 million which beat the analyst consensus estimate of $517.35 million by 1.11 percent. This is a 4.29 percent increase over sales of $501.56 million the same period last year.

Earnings

BOKF

BOK Financial Q4 EPS $2.12 Beats $2.00 Estimate, Sales $523.09M Beat $517.35M Estimate

Contracts

EnerSys Completes Contract And Funding Negotiations With US Department of Energy, Securing $199M Award From Office of Manufacturing and Energy Supply Chains

Management

Diana Shipping Announced Maria Dede As Co-Chief Financial Officer For Operations Finance; Ioannis Zafirakis Continues As Co-Chief Financial Officer For Strategic Finance

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) reported its Q4 earnings results on Friday, January 17, 2025 at 04:03 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
BOK Financial beat estimated earnings by 7.000000000000001%, reporting an EPS of $2.12 versus an estimate of $1.99.
Revenue was up $21.53 million from the same period last year.
<h3>Overview of Past Earnings</h3>
The company beat on EPS by $0.2 in the last quarter, resulting in a 2.0% drop share price change the following day.
Here's a look at BOK Financial's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.98</td>
<td>2.34</td>
<td>1.73</td>
<td>1.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.18</td>
<td>2.02</td>
<td>1.91</td>
<td>1.76</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>510.58M</td>
<td>515.37M</td>
<td>480.76M</td>
<td>490.40M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>516.31M</td>
<td>555.73M</td>
<td>455.27M</td>
<td>501.56M</td>
</tr>
</tbody>
</table>

To track all earnings releases for BOK Financial <a href="https://www.benzinga.com/quote/BOKF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: BOK Financial Q4

GBTG

Global Business Travel Group Enters Into Amended Merger Agreement With CWT Holdings; "Drop Dead Date" Changed To March 17, 2025

Nature's Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology and infrastructure, today issued the following statement in response to the delisting notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq"), which indicated that the Nasdaq Hearings Panel has determined to delist the Company's common stock and warrants from Nasdaq due to the Company's failure to comply with minimum shareholder's equity requirement under Nasdaq Listing Rule 5550(b)(1). Trading in the Company's common stock and warrants was suspended effective at the open of business on January 15, 2025. The Company's common stock and warrants continue to trade on OTC Pink Sheet until the Company relists with Nasdaq.
The Company believes it presented a strong plan to the Nasdaq Hearings Panel, including that the Company entered into a Securities Purchase Agreement ("SPA") with an institutional investor on January 10, 2025. The SPA was disclosed to the public on January 13, 2025, along with details of its closing conditions. This announcement, however, led to a 40% decline in the Company's stock price on the same day.

NMHI

Nature's Miracle Faces Nasdaq Delisting Due To Equity Issues; Trades On OTC Pink Sheet; SPA With Institutional Investor Announced; Exploring Mergers And Acquisitions To Strengthen Position

Adams Resources & Energy Faces Two Lawsuits Over Merger Disclosures; Believes Claims Asserted In Litigation Matters Are Without Merit

WIIM

MRNA

Moderna shares are trading higher after the company announced it's receiving ongoing support from the U.S. HHS to accelerate the development of its mRNA-based pandemic influenza vaccines.

SBUX

Starbucks Announces Next Phase Of Back To Starbucks Initiative To Transform Global Support Teams; Focus On Four-Minute Wait, Parental Leave, And Pricing Transparency; Job Cuts Expected By March

Hingham Institution (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIFS#NASDAQ">HIFS</a>) reported quarterly earnings of $2.16 per share. This is a 154.12 percent increase over earnings of $0.85 per share from the same period last year. The company reported $13.44 million in sales this quarter. This is a 43.37 percent increase over sales of $9.38 million the same period last year.

HIFS

Hingham Institution Q4 Adj. EPS $2.16 Up From $0.85 YoY, Sales $13.44M Up From $9.38M YoY

<h3>Gainers</h3>
<ul>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares moved upwards by 29.7% to $19.5 during Friday's pre-market session. The market value of their outstanding shares is at $593.3 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 25.88% to $0.09. The company's market cap stands at $1.4 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock increased by 18.74% to $1.14. The company's market cap stands at $6.8 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock moved upwards by 18.65% to $2.35. The company's market cap stands at $13.3 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock increased by 14.36% to $1.99. The company's market cap stands at $6.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares rose 13.66% to $1.83. The market value of their outstanding shares is at $21.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 21.6% to $0.1 during Friday's pre-market session. The market value of their outstanding shares is at $12.7 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock declined by 17.78% to $0.31. The market value of their outstanding shares is at $1.5 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares declined by 12.29% to $0.15. The market value of their outstanding shares is at $11.9 million. </li>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares decreased by 7.69% to $16.7. The market value of their outstanding shares is at $399.8 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 7.17% to $3.11. The company's market cap stands at $2.1 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares declined by 6.88% to $0.49. The company's market cap stands at $10.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEON

ANAB

BLRX

CHRO

GCTK

IMRN

MBRX

PRTC

RNAZ

SCPX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) shares increased by 57.7% to $3.69 during Friday's pre-market session. The market value of their outstanding shares is at $51.2 million. </li>
<li>Capital Clean Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCEC#NASDAQ">CCEC</a>) shares increased by 20.21% to $22.0. The company's market cap stands at $1.2 billion. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock moved upwards by 19.98% to $1.8. The market value of their outstanding shares is at $21.4 million. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) shares moved upwards by 13.63% to $2.0. The company's market cap stands at $43.0 million. </li>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) shares moved upwards by 12.14% to $2.49. The market value of their outstanding shares is at $15.9 million. </li>
<li>Caravelle Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock rose 11.72% to $4.48. The company's market cap stands at $249.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) shares fell 11.9% to $28.34 during Friday's pre-market session. The market value of their outstanding shares is at $991.3 million. </li>
<li>Marten Transport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRTN#NASDAQ">MRTN</a>) stock fell 8.98% to $15.01. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) shares declined by 8.65% to $2.43. The company's market cap stands at $82.1 million. </li>
<li>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) stock decreased by 8.54% to $14.25. The market value of their outstanding shares is at $1.8 billion. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares declined by 7.96% to $0.41. The market value of their outstanding shares is at $9.8 million. </li>
<li>JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) shares fell 6.25% to $174.58. The company's market cap stands at $17.5 billion. As per the news, the Q4 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCEC

CECO

FLNC

HTCO

JBHT

KITT

MRTN

NCEW

PSIG

SHIM

ZBAI

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) stock increased by 27.7% to $6.08 during Friday's pre-market session. The market value of their outstanding shares is at $31.9 million. </li>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) stock moved upwards by 20.23% to $2.02. The company's market cap stands at $93.0 million. </li>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares increased by 16.62% to $1.75. The company's market cap stands at $63.2 million. </li>
<li>Arqit Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) stock moved upwards by 15.09% to $32.55. The company's market cap stands at $407.0 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 11.38% to $1.37. The market value of their outstanding shares is at $49.0 million. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) stock increased by 10.91% to $4.83. The company's market cap stands at $379.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) shares declined by 16.2% to $0.26 during Friday's pre-market session. The company's market cap stands at $6.2 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares fell 9.85% to $0.94. </li>
<li>Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) stock decreased by 7.76% to $10.11. The company's market cap stands at $958.1 million. </li>
<li>Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) stock declined by 7.19% to $35.8. The company's market cap stands at $173.5 million. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) stock fell 7.17% to $10.1. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) shares decreased by 6.72% to $3.72. The company's market cap stands at $102.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRE

BTCT

ENFN

FOXO

LAES

MOBX

NVNI

QMCO

QUBT

SOBR

UPLD

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Poolbeg Pharma announces board role change and launch of EIP

Poolbeg Pharma announces cash balance of £12.2M as at 31 Dec 2023

Poolbeg Pharma to voluntarily delist from OTCQB market

POLBF

Press Releases

Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate

Poolbeg Pharma PLC Announces Appointment of Joint Broker

Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023

Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA

Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office

Comments

Poolbeg Pharma

Poolbeg Pharma (POLBF) Forecast

Poolbeg Pharma (OTC:POLBF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga